Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Inclisiran is a short interfering ribonucleic acid (RNA) (siRNA) directed against a protease (PCSK9) that regulates plasma levels of low-density lipoprotein cholesterol (LDL-C), leading to a decrease in plasma LDL cholesterol concentrations. Subcutaneous administration in a repeated dose at 3 months and every 6 months thereafter.
At the time of the last update, we found no published data on its excretion in breast milk..
Its very high molecular weight and volume of distribution make it unlikely to pass into breast milk in clinically significant quantities.
Its null oral bioavailability prevents it from passing into infant plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tract and is not absorbed, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.
Several medical societies/expert authors consider safe the use of this medication during lactation (LactMed).
For considerations on the appropriateness of lipid-lowering therapy during lactation see Maternal hyperlipidemia, hypercholesterolemia, hypertriglyceridemia.
See below the information of this related product: